LON:TRX Tissue Regenix Group (TRX) Share Price, News & Analysis GBX 0.07 0.00 (0.00%) As of 01/6/2026 Add Compare Share Share Stock Analysis Stock Analysis About Tissue Regenix Group Stock (LON:TRX) Get Tissue Regenix Group alerts:Sign Up Key Stats Today's Range 0.07▼ 0.0750-Day Range 0.07▼ 0.0752-Week Range 4.77▼ 66VolumeN/AAverage Volume169,613 shsMarket Capitalization£51.65 thousandP/E RatioN/ADividend Yield4.12%Price TargetN/AConsensus RatingN/A Company Overview Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care. In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures. Read More Receive TRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRX Stock News HeadlinesTissue Regenix Group PLCApril 22, 2026 | marketwatch.comCellRight Tech: Private Equity Funding SecuredJanuary 8, 2026 | finance.yahoo.comYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills. | Profits Run (Ad)CellRight Technologies, LLC Announces Update and Senior Leadership ChangesOctober 21, 2025 | finance.yahoo.comTissue Regenix Group PLC (LSE:TRX) Full Year 2024 Earnings Call Highlights: Record Profit and ...July 3, 2025 | finance.yahoo.comTissue Regenix Scraps Sale Plans, Flags Profit AheadApril 8, 2025 | marketwatch.comTissue Regenix Group Regulatory NewsFebruary 18, 2025 | lse.co.ukTissue Regenix Group Share Chat (TRX)November 3, 2024 | lse.co.ukSee More Headlines TRX Stock Analysis - Frequently Asked Questions How have TRX shares performed this year? Tissue Regenix Group's stock was trading at GBX 0.07 on January 1st, 2026. Since then, TRX shares have increased by 0.0% and is now trading at GBX 0.07. How were Tissue Regenix Group's earnings last quarter? Tissue Regenix Group plc (LON:TRX) announced its quarterly earnings results on Wednesday, September, 2nd. The company reported GBX (0.16) earnings per share (EPS) for the quarter. Tissue Regenix Group had a negative net margin of 2.49% and a negative trailing twelve-month return on equity of 2.38%. What other stocks do shareholders of Tissue Regenix Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tissue Regenix Group investors own include Tesla (TSLA), Agnico Eagle Mines (AEM), Boeing (BA), Bloom Energy (BE), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD) and CareDx (CDNA). Industry, Sector and Symbol Stock ExchangeLON SectorMaterials Industry Metals & Mining Sub-IndustryPrecious Metals & Minerals Current SymbolLON:TRX CIKN/A Webwww.tissueregenix.com Phone+44-1904-567609FaxN/AEmployees120Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.11 million Net Margins-2.49% Pretax MarginN/A Return on Equity-2.38% Return on Assets0.50% Debt Debt-to-Equity Ratio35.10 Current Ratio3.46 Quick Ratio2.36 Sales & Book Value Annual Sales£27.75 million Price / Sales0.00 Cash FlowGBX 0.01 per share Price / Cash Flow5.70 Book ValueGBX 41.58 per share Price / Book0.00Miscellaneous Outstanding Shares71,235,000Free FloatN/AMarket Cap£51.65 thousand OptionableNot Optionable Beta1.61 Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (LON:TRX) was last updated on 1/6/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tissue Regenix Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tissue Regenix Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.